Medical/Pharmaceuticals

MGI Announces Commercial Availability of HotMPS Sequencing Chemistry*and Instrument**in the United Kingdom

SHENZHEN, China, July 28, 2022 /PRNewswire/ -- MGI Tech (MGI) announced that its innovative HotMPS sequencing chemistry* and instrument** are commercially available in theUnited Kingdom, from 23rd June 2022. Further details will be communicated during the 17th Annual Meeting of the International ...

2022-08-04 22:50 2413

Genesis Capital invests in Crux Biolabs, a leading bioanalytical laboratory to the clinical trials sector

* Crux Biolabs is a decade-old Australian leader in bioanalytics, customised biomarker detection, cell assay development, clinical and pre-clinical testing with particular strength in the immuno-oncology clinical trials market * Genesis Capital is partnering with existing management to expand ...

2022-08-04 22:01 3079

Ascletis Announces IND Filing of Oral RdRp Inhibitor ASC10 for COVID-19 Accepted by China NMPA

HANGZHOU, China and SHAOXING, China, Aug. 4, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces that the Investigational New Drug (IND) application of ASC10, an oral inhibitor drug candidate targeting RNA-dependent RNA polymerase (RdRp) for COVID-19, has been accep...

2022-08-04 08:10 2405

HIGHLIGHTS FROM THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE 2022

SAN DIEGO, Aug. 3, 2022 /PRNewswire/ -- New research reported at the Alzheimer's Association International Conference® (AAIC®) 2022 covered the breadth of Alzheimer's and dementia research, including the basic biology of aging and the brain, risk factors and prevention strategies, and caregiving ...

2022-08-03 20:00 1795

HISTORY OF HYPERTENSIVE DISORDERS DURING PREGNANCY LINKED TO INCREASED RISK OF DEMENTIA

SAN DIEGO, Aug. 3, 2022 /PRNewswire/ --Experiences of high blood pressure disorders during pregnancy are associated with an increased risk of vascular dementia and accelerated brain aging, according to studies reported today at the Alzheimer's Association International Conference®(AAIC®) 2022 in S...

2022-08-03 20:00 2077

TikoMed's ILB® activates the body's natural repair signals to restore glutamate homeostasis, amino acid metabolism and neurocognitive functions in a rat model of severe traumatic brain injury

VIKEN, Sweden, Aug. 3, 2022 /PRNewswire/ -- A new study with TikoMed's lead drug candidate, ILB®, addressing underlying causes of neurodegeneration in acute and chronic diseases, was published in the International Journal of Molecular Sciences today. The data from the rodent model studying severe...

2022-08-03 17:23 1240

Ascletis Announces FDA Clearance of Oral RdRp Inhibitor ASC10 to Conduct a Randomized, Placebo Controlled Phase Ib Study in Mild-to-Moderate COVID-19 Patients

-- ASC10 is an oral double prodrug that is rapidly and completely converted in vivo into the active metabolite ASC10-A, which is the same active metabolite of molnupiravir -- Ascletis has filed multiple patent applications for ASC10 and its use globally. Compared with molnupiravir, ASC10 has a n...

2022-08-03 16:50 2086

Technology Solutions to Boost Employee Experience and Improve Patient Outcomes

Workforce management solutions from DXC and SAP support healthcare providers in managing their teams while focusing on employees' well-being and ability to deliver quality care SAN ANTONIO, Aug. 3, 2022 /PRNewswire/ -- Healthcare providers may find that supporting their care team and managing th...

2022-08-03 15:12 1742

Yidu Tech Releases FY2022 ESG Report, Using Socially Beneficial Technology to Drive the Sustainable Development of "Green Healthcare"

HONG KONG, Aug. 3, 2022 /PRNewswire/ -- The digital economy powered by innovative technologies such as artificial intelligence ("AI") and big data has become one of the most powerful drivers of economic growth since the COVID-19 outbreak, in keeping withChina's core strategy of "digitalization, ...

2022-08-03 15:09 1808

Vela Diagnostics Supports COVID-19 Surveillance Efforts in Kenya

HAMBURG, Germany, Aug. 3, 2022 /PRNewswire/ -- Vela Diagnostics has announced its appointment by the National Public Health Laboratory ofKenya (NPHL) as their supplier for SARS-CoV-2 genotyping tests, with funding from The Global Fund. The NPHL operates under Kenya's Ministry of Health and plays...

2022-08-03 14:00 1757

Lim Chin Hau and Medicap Sdn Bhd Awarded at the Asia Pacific Enterprise Awards 2022 Malaysia

KUALA LUMPUR, Malaysia, Aug. 3, 2022 /PRNewswire/ -- Enterprise Asia, the organizer of the 13th Asia Pacific Enterprise Awards (APEA) 2022 Malaysia, is pleased to recognize 47 exceptional business leaders and enterprises that have played a vital role in shapingMalaysia's entrepreneurial landscape...

2022-08-03 13:12 2244

Approval Of The Comparative Study Between ReCOV And mRNA Vaccines By FDA In The Philippines

TAIZHOU, China, Aug. 3, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the"Company", together with its subsidiaries, the "Group",Stock code:02179.HK) is pleased to announce that, the Company has recently received the clinical trial approval for its recombinant protein COVID-19 vaccine,...

2022-08-03 13:09 2757

Antengene Announces First Patient Dosed in the PROBE-CN Study of ATG-101 (PD-L1/4-1BB Bispecific Antibody) for the Treatment of Solid Tumors and Non-Hodgkin Lymphoma

* ATG-101 is a novel PD-L1/4-1BB bispecific antibody. It is Antengene's first in-house developed molecule with global rights. *  ATG-101 demonstrates potent in vivo efficacy in anti-PD-1/PD-L1 resistant mouse tumor models. SHANGHAI and HONG KONG, Aug. 3, 2022 /PRNewswire/ -- Antengene Corpora...

2022-08-03 08:30 1850

Sciwind Biosciences Announces Positive Topline Results from 20-week Phase 2 Clinical Trial of XW003 (Ecnoglutide), a novel long-lasting GLP-1 analogue, in Adult Patients with Type 2 Diabetes in China

-  Robust HbA1c reduction of 2.4% was observed with 1.2 mg XW003 dose -  Up to 88% of participants achieved HbA1c ≤ 7% and up to 72% achieved HbA1c ≤6.5% at the end of the 20-week treatment -  XW003 was safe and well tolerated with gastrointestinal side effects as the most commonly reported adve...

2022-08-03 08:00 1772

Lynk Pharmaceuticals Announces IND Approval of LNK01004 for Atopic Dermatitis in China

HANGZHOU, China, Aug. 3, 2022 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as 'Lynk Pharmaceuticals'), an innovative clinical stage company, announced that its innovative drug LNK01004, has been approved by National Medical Products Administration (NMPA) for clinical tr...

2022-08-03 08:00 2343

Ablaze Pharma Aligned The Strategic Agreement With Wenjiang District Government of Chengdu to Build-up the Innovative R&D and Manufacturing Center for Targeted Radiopharmaceutical Therapies

SHANGHAI, Aug. 3, 2022 /PRNewswire/ -- In July 2022, Ablaze Pharma and Wenjiang District Government ofChengdu jointly signed the strategic agreement during the Conference of Major Advanced Manufacturing Projects by Foreign Direct Investment. About 26,000㎡ of industrial land is selected in the Che...

2022-08-03 08:00 1824

LOWER SOCIOECONOMIC STATUS IN CHILDHOOD, PERSISTENT LOW WAGES LINKED TO RISK FOR DEMENTIA AND FASTER MEMORY DECLINE

SAN DIEGO, Aug. 3, 2022 /PRNewswire/ -- Socioeconomic deprivation, including neighborhood disadvantages and persistent low wages, are associated with higher dementia risk, lower cognitive performance and faster memory decline, according to several studies reported today at theAlzheimer's Associat...

2022-08-03 00:15 2421

Context Therapeutics and The Menarini Group Announce Clinical Trial Collaboration and Supply Agreement to Evaluate ONA-XR and Elacestrant Combination

Preclinical data support the potential of ONA-XR plus estrogen receptor degraders in endocrine resistant disease models Context to initiate Phase 1b/2 clinical trial in Q4 2022 PHILADELPHIA and FLORENCE, Italy, Aug. 2, 2022 /PRNewswire/ -- Context Therapeutics Inc. ("Context" or the "Company") (...

2022-08-02 22:49 2506

Metabolon Awarded ISO 9001:2015 Recertification

ISO 9001:2015 certificate re-issued to Metabolon following continued demonstrated ability to meet customer, statutory, and regulatory standards MORRISVILLE, N.C., Aug. 2, 2022 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions that advance drug development and ...

2022-08-02 20:57 1583

Sironax Announces Closing of $200 Million Series B Financing

Financing from new and existing investors will support pipeline progression and expansion for age-related degenerative diseases BEIJING, Aug. 2, 2022 /PRNewswire/ -- Sironax, an emerging biotechnology company dedicated to the discovery and global development of novel treatments for patients with...

2022-08-02 19:00 1938
1 ... 127128129130131132133 ... 382